Miruna Bala

BC Cancer Agency

Papers

1

Total Citations

42

H-Index

1

About

Miruna Bala is a leading molecular diagnostics researcher whose work centers on the development and clinical validation of next-generation sequencing assays for hereditary cancer risk assessment. Her most impactful contribution is a landmark 2013 study describing a clinically validated second-generation sequencing assay for detecting hereditary BRCA1 and BRCA2 mutations. This work, which has garnered 42 citations, established a critical framework for transitioning BRCA testing from traditional Sanger sequencing to more scalable, high-throughput platforms. By demonstrating the assay's clinical accuracy and reliability, Bala helped pave the way for broader, more accessible genetic screening for breast and ovarian cancer susceptibility. Her research directly addresses the translational gap between genomic technology and patient care, ensuring that diagnostic tools meet rigorous clinical standards. Bala’s contributions are particularly notable for their emphasis on validation and reproducibility, making her a key figure in the adoption of next-generation sequencing in hereditary cancer diagnostics. Her work continues to inform best practices for clinical laboratories implementing BRCA testing.

Research Focus

Key Achievements

1
H-Index
1
Papers
42
Total Citations
42
Avg Citations/Paper
🏆 Most Cited Paper
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations
42 citations · 2013
📈 Most Prolific Year: 2013 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: BC Cancer Agency

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago